Abstract:Abstract Introduction Venous thromboembolism(VTE) is a leading cause of death in patients with lung cancer. Furthermore, hospitalization of patients with advanced lung cancer for VTE treatment represents a major economic burden on the national public health resources. Therefore, we performed this prospective study to identify clinical biomarkers for the early identification of VTE in lung cancer patients. Methods This prospective study enrolled 158 patients with confirmed lung cancer, including 27 who were diagnosed with VTE within six months of the follow-up after lung cancer diagnosis. Multivariate logistic regression analysis was used to evaluate the diagnostic performancese of all the relevant clinical features and laboratory indicators in identifying lung cancer patients with a higher risk of VTE. A novel risk prediction model was constructed consisting of five clinical variables with the best diagnostic performances and was validated using the receiver operation characteristic(ROC) curves. The diagnostic performances of the new risk prediction model was also compared with the Khorana risk score (KRS) and the Padua risk score (PRS). Results The VTE group of lung cancer patients (n = 27) showed significantly higher serum levels of fibrin degradation products (FDP), D-dimer, thrombomodulin (TM), thrombin-antithrombin-complex (TAT), α2-plasmin inhibitor-plasmin Complex (PIC), and tissue plasminogen activator-plasminogen activator inhibitor complex (t-PAIC) compared to those in the non-VTE group (n = 131). ROC curve analyses showed that the diagnostic efficacy of the new VTE risk prediction model with TM ≥ 9.75 TU/ml, TAT ≥ 2.25ng/ml, t-PAIC ≥ 7.35ng/ml, history of VTE, and ECOG PS score ≥ 2 was superior than the KRS and the PRS in the early identification of lung cancer patients with a higher risk of VTE. Conclusions The new risk prediction model showed significantly high diagnostic efficacy in the early identification of lung cancer patients with a high risk of VTE. The diagnostic efficacy of the new risk prediction model was higher than the KRS and the PRS in this cohort of lung cancer patients.

Advances in the Prediction and Risk Assessment of Lung Cancer-Associated Venous Thromboembolism

Early Identification of Lung Cancer Patients with Venous Thromboembolism: Development and Validation of a Risk Prediction Model.

A systematic review of risk prediction model of venous thromboembolism for patients with lung cancer

Establishment and Validation of a Risk Prediction Model for Venous Thromboembolism in Lung Cancer Based on a Meta-Analysis

Risk Factors and Prognosis Value of Venous Thromboembolism in Patients with Advanced Non-Small Cell Lung Cancer: a Case-Control Study

Risk Factors and Prediction Models for Venous Thromboembolism in Ambulatory Patients with Lung Cancer

Venous thromboembolism in non-small-cell lung cancer patients:Report of 15 cases

Risk Prediction of Malignant Tumor Related Venous Thrombosis

Lung Cancers Combined With Venous Thromboembolism: A Case Report

Management of Venous Thromboembolism in Patients with Lung Cancer: a State-of-the-art Review

[Retrospective Analysis of Risk Factors for Venous Thromboembolism in 283 Patients with Lung Cancer During Systemic Therapy].

Prevalence and clinical characteristics of venous thromboembolism in patients with lung cancer: a systematic review and meta-analysis

Development and Validation of a Risk Prediction Model for Venous Thromboembolism in Lung Cancer Patients Using Machine Learning

Models for predicting venous thromboembolism in ambulatory patients with lung cancer: A systematic review and meta-analysis

Venous Thromboembolism in Lung Cancer with Clinical Analysis of 89 Cases

Diagnosis and Treatment Characteristics of Lung Cancer Patients with Venous Thromboembolism

Advances in Cancer Related Venous Thromboembolism Research

Comparison among Different Presentations of Venous Thromboembolism Because of Lung Cancer

Nomogram Prediction for the Risk of Venous Thromboembolism in Patients with Lung Cancer

Development and validation of a predictive score for venous thromboembolism in newly diagnosed non-small cell lung cancer

Research progress on venous thrombosis development in patients with malignant tumors